BioNTech SE (BNTX) Stock Forecast & Price Target

Compare

4,600 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BNTX Analyst Ratings

Moderate Buy

14 Buy

5 Hold

0 Sell

Based on 19 analysts giving stock ratings to

BioNTech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BNTX Stock 12 Month Forecast

Average Price Target

$140.10

▲(32.00%Upside)

Based on 19 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $140.10 with a high forecast of $181.00 and a low forecast of $108.49. The average price target represents a 32.00% change from the last price of $106.14.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"77":"$77","182":"$182","103.25":"$103.3","129.5":"$129.5","155.75":"$155.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":181,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$181.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$140.10</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.49,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$108.49</span>\n  </div></div>","useHTML":true}}],"tickPositions":[77,103.25,129.5,155.75,182],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.1,118.32307692307691,123.54615384615384,128.76923076923077,133.9923076923077,139.2153846153846,144.43846153846152,149.66153846153844,154.8846153846154,160.1076923076923,165.33076923076922,170.55384615384617,175.77692307692308,{"y":181,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.1,115.17692307692307,117.25384615384615,119.33076923076922,121.4076923076923,123.48461538461538,125.56153846153846,127.63846153846154,129.7153846153846,131.7923076923077,133.86923076923077,135.94615384615383,138.02307692307693,{"y":140.1,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,113.1,112.74538461538461,112.39076923076922,112.03615384615384,111.68153846153845,111.32692307692307,110.97230769230768,110.61769230769231,110.26307692307692,109.90846153846154,109.55384615384615,109.19923076923077,108.84461538461538,{"y":108.49,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.6,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.83,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.68,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.22,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.93,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":117.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$181.00

Average Price Target$140.10

Lowest Price Target$108.49

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$109

Hold

2.69%

Upside

Reiterated

06/25/25

BioNTech's overall stock score of 58 reflects the company's robust financial position and strategic advancements in oncology and vaccine development as key strengths. However, significant financial challenges, including ongoing losses, high R&D expenses, and settlement costs, weigh heavily on the score. The technical analysis and valuation further underscore the need for cautious optimism, given the current neutral trend and negative P/E ratio.

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/27/25

Truist Financial Remains a Buy on BioNTech SE (BNTX)

Geoff MeachamCiti

Citi

$140

Buy

31.90%

Upside

Reiterated

06/25/25

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Thermo Fisher (TMO)

Robert BurnsH.C. Wainwright

H.C. Wainwright

$138

Buy

30.02%

Upside

Reiterated

06/25/25

BioNTech SE: Orphan Drug Designation and Valuation Support Buy Rating

Terence FlynnMorgan Stanley

Morgan Stanley

$132

Buy

24.36%

Upside

Reiterated

06/23/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

$140

Buy

31.90%

Upside

Reiterated

06/13/25

Deutsche Bank Remains a Buy on BioNTech SE (BNTX)

Evan SeigermanBMO Capital

BMO Capital

$143

Buy

34.73%

Upside

Reiterated

06/12/25

BioNTech SE's Strategic Acquisition of CureVac Bolsters mRNA Therapeutics and Growth Potential

Tazeen AhmadBank of America Securities

Bank of America Securities

$127

Buy

19.65%

Upside

Reiterated

06/12/25

Strategic Acquisition and Pipeline Synergies Drive Buy Rating for BioNTech

John NewmanCanaccord Genuity

Canaccord Genuity

$171

Buy

61.11%

Upside

Reiterated

06/12/25

BioNTech's Strategic Acquisition of CureVac: Enhancing mRNA Platform and Market Position

Daina GrayboschLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/12/25

Analysts Are Bullish on Top Healthcare Stocks: Schrodinger (SDGR), Celldex (CLDX)

Harry GillisBerenberg Bank

Berenberg Bank

$130→$150

Buy

41.32%

Upside

Reiterated

06/03/25

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Sanofi (SNYNF)

William MaughanClear Street

Clear Street

$155→$181

Buy

70.53%

Upside

Reiterated

06/02/25

Clear Street Remains a Buy on BioNTech SE (BNTX)

Akash TewariJefferies

Jefferies

$149→$151

Buy

42.26%

Upside

Reiterated

06/02/25

Jefferies Keeps Their Buy Rating on BioNTech SE (BNTX)

Hartaj SinghOppenheimer

Oppenheimer

―

Hold

―

Reiterated

06/02/25

Oppenheimer Sticks to Their Hold Rating for BioNTech SE (BNTX)

Mohit BansalWells Fargo

Wells Fargo

$200→$170

Buy

60.17%

Upside

Reiterated

06/02/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$109

Hold

2.69%

Upside

Reiterated

06/25/25

Asthika GoonewardeneTruist Financial

Truist Financial

―

Buy

―

Reiterated

06/27/25

Truist Financial Remains a Buy on BioNTech SE (BNTX)

Geoff MeachamCiti

Citi

$140

Buy

31.90%

Upside

Reiterated

06/25/25

Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Thermo Fisher (TMO)

Robert BurnsH.C. Wainwright

H.C. Wainwright

$138

Buy

30.02%

Upside

Reiterated

06/25/25

BioNTech SE: Orphan Drug Designation and Valuation Support Buy Rating

Terence FlynnMorgan Stanley

Morgan Stanley

$132

Buy

24.36%

Upside

Reiterated

06/23/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Vertex Pharmaceuticals (NASDAQ: VRTX) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

$140

Buy

31.90%

Upside

Reiterated

06/13/25

Deutsche Bank Remains a Buy on BioNTech SE (BNTX)

Evan SeigermanBMO Capital

BMO Capital

$143

Buy

34.73%

Upside

Reiterated

06/12/25

BioNTech SE's Strategic Acquisition of CureVac Bolsters mRNA Therapeutics and Growth Potential

Tazeen AhmadBank of America Securities

Bank of America Securities

$127

Buy

19.65%

Upside

Reiterated

06/12/25

Strategic Acquisition and Pipeline Synergies Drive Buy Rating for BioNTech

John NewmanCanaccord Genuity

Canaccord Genuity

$171

Buy

61.11%

Upside

Reiterated

06/12/25

BioNTech's Strategic Acquisition of CureVac: Enhancing mRNA Platform and Market Position

Daina GrayboschLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/12/25

Analysts Are Bullish on Top Healthcare Stocks: Schrodinger (SDGR), Celldex (CLDX)

Harry GillisBerenberg Bank

Berenberg Bank

$130→$150

Buy

41.32%

Upside

Reiterated

06/03/25

Analysts Are Bullish on Top Healthcare Stocks: Nurix Therapeutics (NRIX), Sanofi (SNYNF)

William MaughanClear Street

Clear Street

$155→$181

Buy

70.53%

Upside

Reiterated

06/02/25

Clear Street Remains a Buy on BioNTech SE (BNTX)

Akash TewariJefferies

Jefferies

$149→$151

Buy

42.26%

Upside

Reiterated

06/02/25

Jefferies Keeps Their Buy Rating on BioNTech SE (BNTX)

Hartaj SinghOppenheimer

Oppenheimer

―

Hold

―

Reiterated

06/02/25

Oppenheimer Sticks to Their Hold Rating for BioNTech SE (BNTX)

Mohit BansalWells Fargo

Wells Fargo

$200→$170

Buy

60.17%

Upside

Reiterated

06/02/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

1 Month

xxx

Success Rate

15/27 ratings generated profit

Average Return

+1.87%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +1.87% per trade.

3 Months

xxx

Success Rate

6/10 ratings generated profit

Average Return

-0.25%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of -0.25% per trade.

1 Year

Tazeen AhmadBank of America Securities

Success Rate

13/23 ratings generated profit

Average Return

-0.08%

reiterated a buy rating 16 days ago

Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 56.52% of your transactions generating a profit, with an average return of -0.08% per trade.

2 Years

xxx

Success Rate

14/23 ratings generated profit

Average Return

+2.85%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 60.87% of your transactions generating a profit, with an average return of +2.85% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BNTX Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BNTX has received 56 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. BNTX average Analyst price target in the past 3 months is 140.10.

Each month's total comprises the sum of three months' worth of ratings.

BNTX Financial Forecast

BNTX Earnings Forecast

Next quarter’s earnings estimate for BNTX is -$2.08 with a range of -$3.84 to $3.75. The previous quarter’s EPS was -$2.00. BNTX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.17% of the time in the same period. In the last calendar year BNTX has Outperformed its overall industry.

BNTX Sales Forecast

Next quarter’s sales forecast for BNTX is $171.28M with a range of $95.00M to $469.35M. The previous quarter’s sales results were $192.39M. BNTX beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 47.47% of the time in the same period. In the last calendar year BNTX has Outperformed its overall industry.

BNTX Stock Forecast FAQ

What is BNTX’s average 12-month price target, according to analysts?

Based on analyst ratings, BioNTech SE’s 12-month average price target is 140.10.

What is BNTX’s upside potential, based on the analysts’ average price target?

BioNTech SE has 32.00% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BNTX a Buy, Sell or Hold?

BioNTech SE has a consensus rating of Moderate Buy which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings.

What is BioNTech SE’s price target?

The average price target for BioNTech SE is 140.10. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $181.00 ,the lowest forecast is $108.49. The average price target represents 32.00% Increase from the current price of $106.14.

What do analysts say about BioNTech SE?

BioNTech SE’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.

How can I buy shares of BNTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BioNTech SE (BNTX) Stock Forecast & Price Target

BNTX Analyst Ratings

BNTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioNTech SE

BNTX Analyst Recommendation Trends

BNTX Financial Forecast

BNTX Earnings Forecast

BNTX Sales Forecast

BNTX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts